Advaccine

Advaccine is a biopharmaceutical company founded in 2009 in China, focusing on advancing vaccines and improving immunotherapeutics. The company has a robust pipeline of prophylactic and therapeutic vaccines targeting diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV), and hepatitis B virus (HBV), addressing significant unmet medical needs. Moreover, Advaccine is also developing cancer vaccine candidates, including those for viral-related oncology, neoantigen-based therapeutic vaccines, and tumor-associated antigen therapeutic vaccines. The company recently secured a $6.60M private equity round investment on 05 April 2021, with participation from Matrix Partners China and Hony Capital. With its in-house developed technology platforms and industrial manufacturing capabilities, Advaccine holds promising potential in the biopharma, biotechnology, and pharmaceutical industries. Its dedication to tackling challenging diseases and advancing immunotherapeutics makes it an attractive prospect for investors.